drugset / Trial / NCT03811652
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.
Timeline
- Start
- 2018-12-20
- Primary completion
- 2019-12-10
- Completion
- 2019-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI7247 | Unknown | — | Intravenous |